We are taking PHC toward a future where treatments are targeted towards individual patient needs and unique profiles.

Partnering opportunities we are looking for:

• Robust data sets (e.g. to enable biomarker discovery and development, power AI/ML algorithms)

• Advanced Analytics (artificial intelligence including machine learning and deep-learning models)

• Digital and mobile technologies (e.g. to optimize treatment administration)

We are leading the way to advance science in inflammatory and autoimmune diseases.

Partnering opportunities we are looking for:

• Gastroenterology (IBD), Respiratory (COPD, Asthma, IPF, ILD, SSc), Nephrology (GN, CKD, Transplant, auto-immune skin diseases (Psoriasis, AD), T1D, Celiac disease

  • Innate, Adaptive, Fibrosis, Tolerance and Tissue Regeneration Targets

We are advancing innovation to combat infectious diseases like HBV, influenza and MDR.

Partnering opportunities we are looking for:

• Hepatitis B

• Respiratory Viruses

• Multidrug-resistant, Gram-negative Bacterial Infections

• Non-tuberculosis mycoplasma

We focus on advances for neurodegenerative, psychiatric and neurodevelopmental disorders.

Partnering opportunities we are looking for:

• Neurodegenerative diseases (e.g. Alzheimer's disease, Parkinson's disease, Huntington disease)

• Neuroimmunology and neuroinflammation (e.g. Multiple sclerosis)

• Neurodevelopment and psychiatry (e.g. Angelman Syndrome, Schizophrenia, and Autism spectrum disorders)

• Neuromuscular diseases (e.g. SMA and Duchenne Muscular Dystrophy)

We focus on first- and best-in-class therapeutics in molecular targeted therapies and cancer immunotherapy.

Partnering opportunities we are looking for:

• Oncogenic drivers

• Synthetic lethality

• Adaptive and innate immunity

• Neoantigens

• Stromal biology

• Cell therapies

We are focusing on saving people’s eyesight from the leading causes of vision loss through pioneering therapies and cutting- edge research.

Partnering opportunities we are looking for:

• Retinal diseases (including AMD, DME, RVO, DR)

• Glaucoma

• Dry eye disease

• Vision restoration through gene therapy and cell-based therapy approaches

We are committed to developing new innovations for monogenetic rare diseases.

Partnering opportunities we are looking for:

• Monogenetic rare diseases

We focus on therapeutic modalities and enabling technologies. Partnering opportunities we are looking for:

• Novel modalities and enabling technologies to expand the druggable target space

• Targeted or intracellular delivery

• Artificial intelligence for target and drug discovery

• Genomic Medicine platforms

Research & Development is the essence and lifeblood of Roche - and we have a unique way to foster innovation together with our partners in Asia and across the world. Partnering opportunities we are looking for:

• Innovative biotechs or academic institutions from Asia working on first in class or best in disease opportunities from Discovery to Phase II Development and;

• Immunology (interferon-driven inflammatory diseases including lupus nephritis and systemic sclerosis, nephrology and renal transplant, with focused MoAs in nucleic acid sensing, interferon production, complement and immune tolerance) and oncology (gastrointestinal cancers, with focused MoAs in novel and/or disease-specific cancer driver genes, synthetic lethality, immunotherapy for enhancing innate immunity and dampening suppression, and cancer extracellular matrix esp. collagen modulation)

Leveraging external innovation has always been central to our R&D strategy and, as such, supporting, encouraging and accessing early stage innovation is a critical aspect of our ability to discover and develop meaningful medicines for patients. Since some of the most cutting-edge science is happening in the UK, we are increasingly focusing on identifying and supporting great science in the UK. We are seeking partnering opportunities across all our therapeutic areas of interest, including digital and personalized healthcare and novel research technologies, in particular for the following:

• Novel targets

• Potential first- or best-in class molecules

• Novel enabling modalities

• Data sets and advanced analytics

• Digital and mobile technologies

During the collaboration conversations, a dedicated Alliance Manager is assigned as the single point of contact to ensure successful continuation and an enduring relationship with our new partner.

Out-licensing and divestment decisions enable us to continue our investment in innovative R&D, supporting the development of novel medicines. In addition,it supports the further development of programs that could result in treatments for patients in disease areas and indications that are no longer of strategic focus for Roche and Genentech.